About 6–12% of all sporadic neuroblastomas are ALK-mutation-positive, with ALK neuroblastoma mutants having three subtypes: ligand-independent, ligand-dependent, or kinase-dead mutants that contain mutations of downstream signaling proteins such as the RAS/MAPK pathway, which includes NF1 mutations and RAF mutations [32]. This evidence concerns the gene ALK and neuroblastoma.